학술논문
Nanoparticles Enhance Solubility and Neuroprotective Effects of Resveratrol in Demyelinating Disease.
Document Type
Academic Journal
Author
Shamsher E; Institute of Ophthalmology, University College London, London, UK.; Jules-Gonin Eye Hospital, Lausanne University, Lausanne, Switzerland.; Khan RS; Departments of Ophthalmology and Neurology, Scheie Eye Institute, University of Pennsylvania, 51 N 39th Street, Philadelphia, PA, 19104, USA.; Davis BM; Institute of Ophthalmology, University College London, London, UK.; Dine K; Departments of Ophthalmology and Neurology, Scheie Eye Institute, University of Pennsylvania, 51 N 39th Street, Philadelphia, PA, 19104, USA.; Luong V; Institute of Ophthalmology, University College London, London, UK.; Somavarapu S; School of Pharmacy, University College London, London, UK.; Cordeiro MF; Institute of Ophthalmology, University College London, London, UK.; Imperial College London Ophthalmology Research Group, London, UK.; Western Eye Hospital, London, UK.; Shindler KS; Departments of Ophthalmology and Neurology, Scheie Eye Institute, University of Pennsylvania, 51 N 39th Street, Philadelphia, PA, 19104, USA. kenneth.shindler@pennmedicine.upenn.edu.
Source
Publisher: Elsevier Inc. on behalf of American Society for Experimental NeuroTherapeutics Country of Publication: United States NLM ID: 101290381 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1878-7479 (Electronic) Linking ISSN: 18787479 NLM ISO Abbreviation: Neurotherapeutics Subsets: MEDLINE
Subject
Language
English
Abstract
Resveratrol is a natural polyphenol which may be useful for treating neurodegenerative diseases such as multiple sclerosis (MS). To date, current immunomodulatory treatments for MS aim to reduce inflammation with limited effects on the neurodegenerative component of this disease. The purpose of the current study is to develop a novel nanoparticle formulation of resveratrol to increase its solubility, and to assess its ability to prevent optic nerve and spinal cord degeneration in an experimental autoimmune encephalomyelitis (EAE) mouse model of MS. Resveratrol nanoparticles (RNs) were made using a thin rehydration technique. EAE mice received a daily oral administration of vehicle, RNs or unconjugated resveratrol for one month. They were assessed daily for clinical signs of paralysis and weekly for their visual acuity with optokinetic responses (OKR). After one month, their spinal cords and optic nerves were stained for inflammation and demyelination and retinal ganglion cells immunostained for Brn3a. RNs were stable for three months. The administration of RNs did not have any effect on clinical manifestation of EAE and did not preserve OKR scores but reduced the intensity of the disease. It did not reduce inflammation and demyelination in the spinal cord and the optic nerve. However, RNs were able to decrease RGC loss compared to the vehicle. Results demonstrate that resveratrol is neuroprotective by reducing RGC loss. Interestingly, neuroprotective effects and decreased disease severity occurred without reduction of inflammation or demyelination, suggesting this therapy may fill an unmet need to limit the neurodegenerative component of MS.
(© 2023. The American Society for Experimental Neurotherapeutics, Inc.)
(© 2023. The American Society for Experimental Neurotherapeutics, Inc.)